Blood cell study may unlock kidney disease secrets
NCT ID NCT05894512
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study looked at immune cells (T and B cells) in the blood of 44 people with a kidney disease called membranous nephropathy. Researchers wanted to see how these cells relate to treatment response and disease relapse. They also measured specific antibodies linked to the disease. The goal was to better understand the disease, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istanbul University
Istanbul, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can a new pill slow kidney damage in IgA nephropathy?
- Can a gut metabolite shield the kidneys in IgA nephropathy?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a pill calm the immune attack on kidneys?